MRKR · Marker Therapeutics, Inc. · Share Buybacks
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-11 | — | $11,431,713 | — | — | 10-Q , filed 2026-08-14 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2018-12-31 | $71,710 | 10-K, filed 2020-03-12 |
| 2017-12-31 | $310,493 | 10-K, filed 2019-03-15 |
| 2016-12-31 | $0 | 10-K, filed 2018-03-23 |